Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim F Greten

Showing results (171-180 of 223) with videos related to

Pageof 23
Sort By:
Anti-Cancer Drugs|September 23, 2009
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'Stefan Boeck, Ursula Vehling-Kaiser, Dirk Waldschmidt, et al.
Clinical and Translational Science|April 3, 2021
A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotypeMarina Baretti, Enusha Karunasena, Marianna Zahurak, et al.
Cancer Immunology, Immunotherapy : CII|January 29, 2019
The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinomaDavid Agdashian, Mei ElGindi, Changqing Xie, et al.
Nature Communications|July 7, 2016
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standardsVincenzo Bronte, Sven Brandau, Shu-Hsia Chen, et al.
Journal for Immunotherapy of Cancer|March 24, 2017
Systematic evaluation of immune regulation and modulationDavid F Stroncek, Lisa H Butterfield, Michael A Cannarile, et al.
Nature Communications|December 8, 2022
Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancerLichun Ma, Sophia Heinrich, Limin Wang, et al.
Clinical Colorectal Cancer|July 29, 2019
A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal CancerCharalampos S Floudas, Gagandeep Brar, Donna Mabry-Hrones, et al.
Gastroenterology|October 3, 2020
Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in MiceBernd Heinrich, Zachary J Brown, Laurence P Diggs, et al.
The Oncologist|March 11, 2022
A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract CarcinomaCecilia Monge, Erica C Pehrsson, Changqing Xie, et al.
Cancer Cell|October 8, 2019
Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver CancerLichun Ma, Maria O Hernandez, Yongmei Zhao, et al.
Pageof 23

Showing results (171-180 of 223) with videos related to

Sort By:
Pageof 23
Anti-Cancer Drugs|September 23, 2009
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'Stefan Boeck, Ursula Vehling-Kaiser, Dirk Waldschmidt, et al.
Clinical and Translational Science|April 3, 2021
A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotypeMarina Baretti, Enusha Karunasena, Marianna Zahurak, et al.
Cancer Immunology, Immunotherapy : CII|January 29, 2019
The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinomaDavid Agdashian, Mei ElGindi, Changqing Xie, et al.
Nature Communications|July 7, 2016
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standardsVincenzo Bronte, Sven Brandau, Shu-Hsia Chen, et al.
Journal for Immunotherapy of Cancer|March 24, 2017
Systematic evaluation of immune regulation and modulationDavid F Stroncek, Lisa H Butterfield, Michael A Cannarile, et al.
Nature Communications|December 8, 2022
Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancerLichun Ma, Sophia Heinrich, Limin Wang, et al.
Clinical Colorectal Cancer|July 29, 2019
A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal CancerCharalampos S Floudas, Gagandeep Brar, Donna Mabry-Hrones, et al.
Gastroenterology|October 3, 2020
Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in MiceBernd Heinrich, Zachary J Brown, Laurence P Diggs, et al.
The Oncologist|March 11, 2022
A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract CarcinomaCecilia Monge, Erica C Pehrsson, Changqing Xie, et al.
Cancer Cell|October 8, 2019
Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver CancerLichun Ma, Maria O Hernandez, Yongmei Zhao, et al.
Pageof 23